Paul Gregor
Chief Executive Officer Gismo Therapeutics Inc.
Seminars
Thursday 5th February 2026
Drugs in Preclinical Development: Targeting Pathological Spreading of Alpha-Synuclein, Beta-Amyloid & Tau
11:00 am
- Molecular mechanisms responsible for prion-like propagation and spreading of misfolded protein aggregates / amyloid proteopathic seeds
- Olfactory bulb injections of alpha-synuclein Preformed Fibrils (PFFs) reproduce slow brain wide spread of alphasynucleinopathy in rodents, mirroring PD
- Preclinical development of a novel Alpha-Synuclein/Beta- Amyloid/Tau/ /glycosaminoglycan inhibitor for PD and AD
